Nonprofit, nonpartisan journalism. Supported by readers.


Medtronic studying pump to deliver hepatitis medication

Medtronic is initiating a study to see whether a technology it developed for treating diabetes might also help patients with the hepatitis C virus.

The Medtronic Paradigm Infusion System is an external pump infusion system currently approved for delivering insulin in patients with diabetes.

The company announced today that it’s started enrolling patients in a clinical study to test the tolerability, safety and effectiveness of using the system to deliver hepatitis C medication.

“With this trial now under way, we have the potential to extend our pump technologies and develop yet another drug-delivery option for a chronic disease that impacts millions of lives,” CEO Bill Hawkins said.

Chronic hepatitis patients can require weekly injections plus oral medication for up to 48 weeks. Medtronic hopes the continuous-delivery system might be more convenient with fewer side effects.

You can also learn about all our free newsletter options.

No comments yet

Leave a Reply